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Case description 
Juvenile breast hypertrophy (JBH), also called virginal hypertrophy or macromastia, is a rare 
benign condition, in which one or both breasts undergo a massive increase in size duringin 
puberty, usually around menarche. We present a clinical case of JBH and discuss the available 
therapeutic options.   
An 11-year- old female patient was referred to our paediatric endocrinologist consultant due 
to breast hypertrophy. She referred witha rapid growth of both breasts with a two2-month 
evolution with and no other symptoms. She presented excessive breast enlargement, with 
inflammatory signs of the peri-areolar skin, intense erythema, as well as bilateral tenderness. 
She was medicated with large broad-spectrum antibiotics and was forwarded to our paediatric 
endocrinologist consultant. Menarche had occurred less than a week beforeearlier. UnderAt 
our observation, she had massive bilateral breast hypertrophy (Fig. 1) with no palpable 
masses and no other alterations to her physical examination. She complained about breast 
pain and social embarrassment. Hormonal levels — including oestradiol, progesterone, LH, 
FSH, and prolactin, were normal, and tumour markers were negative. The breast ultrasound 
reported showed hypertrophy of the breast tissue bilaterally with signs of interstitial and 
subcutaneous oedema. Pelvic ultrasound revealed no abnormalities. She was referred to a 
psychology as well as a plastic surgery consultant.  
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Juvenile breast hypertrophy (JBH) was first described in 1669 [1, 2]. It is characteriszed by 
rapid unilateral or bilateral disproportional overgrowth of the breasts during the peripubertal 
period [4]. Most cases are sporadic with rare familial incidence [2, 3]. The classical history is 
a sudden increase in breast size shortly after telarche [2, 4]. Although it is of unclear 
aetiology, the most popular theories include end-organ hypersensitivity to normal levels of 
circulating oestrogen, increased oestrogen or progesterone receptor expression, imbalance of 
endogenous hormone production, and excessive local oestrogen production [1, 3, 4]. Recent 
studies have suggested a genetic basis for this disease, involving the phosphatase and tensin 
homologue tumour suppressing gene, although clinical correlation is still unclear [4, 5]. 
Juvenile breast hypertrophy is a benign condition, but this diagnosise can only be made only 
after a detailed history, thorough physical examination, and after excluding underlying 
conditions such as endocrine and malignant disorders. Physical examination may reveal skin 
changes including erythema, inflammation, striae, thinning, and prominent veins [4]. In 
addition to the physical hazards (— neck, shoulder, and back pain are frequent complaints), 
this condition may entail numerous psychological consequences, due to the enlarged breast 
mass in such a critical developmental phase, and patients frequently complaint of 
embarrassment and social isolation [5]. Laboratory tests including endocrinology profile are 
not routinely indicated as because theyit rarely reveals abnormalities [2, 5]. On the other 
hand, breast imaging (— breast ultrasound or MRI) — is extremely important in order to 
exclude tumours, although in this particular condition it presents several limitations due to 
dense breast tissue [2, 5]. Spontaneous resolution is rare, and the definitive treatment and it’s 
timely management is the most challenging aspect of JHB [2, 5]. Therapeutic options include 
surgical management and medical therapy, although there is no formal guideline [2–4].  
The gist of medical treatment consists of hormone-modulators, which, at best, may lead to 
breast growth arrest without size reduction or symptom alleviation [5]. Drugs such as 
tamoxifen, dydrogesterone, medroxyprogesterone, bromocriptine, and danazol have been 
attempted used in different cases, with limited results and questionable long- term safety. 
Tamoxifen is a selective oestrogen receptor modulator and the most commonly used [2–5] as 
well as the most effective [4, 5]; however, there is no evidence- based recommendation 
concerning the dosage and duration of therapy [7]. The most commonly surgical therapy 
consists of reduction mammoplasty, which must be delayed until full breast development 
because, as there is a high rate of recurrence when growth stability is not achieved prior to 
surgery, leading to subsequent surgical procedures associated with significant morbidity [3–
5]. The most well accepted surgical treatment consists of breast reduction followed by 
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mastectomy with implant reconstruction in cases of recurrence [2]. However, there are several 
cases of success with breast- reduction surgery [1], and it was our option for this particular 
patient. A combination of both medical and surgicalery treatment has also been conducted in 
some patients, with variable results –, as in some cases breast enlargement developeds after 
tamoxifen wais stopped [4, 5]. BecauseAs JBH results in severe psychosocial problems, it is 
of paramount importance for these adolescents to have psychological monitoring during this 
difficult period because, as hardships with body image, poor self-esteem, and difficulty to 
fitting in are often present.  
 
 
 
 
 
 
 
 
 
Figure 1. Juvenile breast hypertrophy (JBH) — massive bilateral breast hypertrophy in an 11-
year- old patient 
 
